Patrick Roberts, Incyclix Bio CEO
Cosela maker's early employees aim to replicate 'blueprint' at a new biotech — with an old G1 asset
Three of the earliest employees at G1 Therapeutics want to repeat the blueprint they laid at securing approval for CDK4/6 inhibitor Cosela by taking a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.